Segall Bryant & Hamill LLC Purchases New Shares in Bioventus Inc. (NYSE:BVS)

Segall Bryant & Hamill LLC acquired a new position in shares of Bioventus Inc. (NYSE:BVS) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 377,824 shares of the company’s stock, valued at approximately $4,515,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Quest Partners LLC bought a new stake in shares of Bioventus during the third quarter valued at approximately $51,000. Acadian Asset Management LLC bought a new position in Bioventus in the 1st quarter valued at $28,000. Covestor Ltd acquired a new stake in shares of Bioventus in the 3rd quarter valued at $69,000. CWM LLC bought a new stake in shares of Bioventus during the third quarter worth $89,000. Finally, Lazard Asset Management LLC acquired a new position in shares of Bioventus during the first quarter valued at $40,000. Institutional investors and hedge funds own 62.94% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. Craig Hallum boosted their price objective on Bioventus from $12.00 to $17.00 and gave the stock a “buy” rating in a report on Friday, September 27th. Canaccord Genuity Group increased their price objective on shares of Bioventus from $12.00 to $15.00 and gave the company a “buy” rating in a report on Wednesday, November 6th.

Bioventus Price Performance

Shares of BVS opened at $11.71 on Friday. The stock has a market cap of $950.27 million, a P/E ratio of -19.20 and a beta of 0.88. Bioventus Inc. has a 1 year low of $3.77 and a 1 year high of $14.38. The stock’s 50-day moving average price is $12.05 and its two-hundred day moving average price is $8.93. The company has a current ratio of 1.41, a quick ratio of 0.99 and a debt-to-equity ratio of 1.85.

Bioventus (NYSE:BVS) last issued its quarterly earnings data on Tuesday, November 5th. The company reported $0.06 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.06. The firm had revenue of $138.96 million during the quarter, compared to analysts’ expectations of $132.57 million. Bioventus had a negative net margin of 7.11% and a positive return on equity of 15.61%. During the same quarter in the previous year, the company earned $0.05 earnings per share. On average, equities analysts predict that Bioventus Inc. will post 0.41 earnings per share for the current year.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.